Frankfurt - Delayed Quote EUR

WuXi Biologics (Cayman) Inc. (1FW2.F)

2.5505

-0.0580

(-2.22%)

At close: April 28 at 8:03:39 AM GMT+2

WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost environmental non-profit reporting organization, for its leadership in disclosure transparency and performance excellence in the area of climate change. This marks the second consecutive year the company has achieved this honor.

PR Newswire 6 days ago

WXIBF

WXXWY
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs) in the second drug substance line of its MFG20 facility at the Hangzhou site. The accomplishment not only marks a significant breakthrough as Asia's first 5,000L drug substance scale-up line utiliz

PR Newswire 10 days ago

WXIBF

WXXWY
WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. This also marks the seventh time that the company has been recognized by the organizer.

PR Newswire 14 days ago

WXIBF

WXXWY
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2024 ("Reporting Period").

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by the environmental non-profit CDP for leadership in corporate transparency and performance on water security, securing a place on the organization's annual "A List" for the second year.

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability Yearbook 2025 ("Yearbook") for its strong sustainability performance in 2024. The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level of recognition.

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics introduces E coli expression system

The platform expedites biotherapeutic advancement for worldwide partners by providing streamlined processes.

Pharmaceutical Technology last month

WXXWY
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of its innovative technology platform, EffiX™, a proprietary E. coli expression system engineered to deliver high yield and exceptional stability in the production of recombinant proteins and plasmid DNA.

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics Again Passed GMP Inspection by Japan PMDA

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city.

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the second year the company has received the rating's highest level of recognition.

PR Newswire 2 months ago

WXIBF

WXXWY
WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, marking the fifth consecutive year the company has scored among the highest in ESG Risk Ratings.

PR Newswire 2 months ago

WXIBF

WXXWY
WuXi Biologics to sell Ireland-based vaccine site to MSD for $500m

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

Pharmaceutical Technology 3 months ago

GLDAF

WXXWY
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager

SAN DIEGO & SHANGHAI, January 07, 2025--Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced today an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBodyTM. Candid plans to complete IND enabling s

Business Wire 3 months ago

WXIBF

WXXWY
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases.

PR Newswire 3 months ago

WXIBF

WXXWY
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the 2024 Dow Jones Sustainability Indices (DJSI), and given among the top scores for its unremitting efforts and notable achievements in promoting sustainable development.

PR Newswire 3 months ago

WXIBF

WXXWY
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the "20 Case Examples for 20 Years: Private Sector's Sustainable Development in China" report initiated by the United Nations Global Compact. The company has been invited to UNGC global roadshow and has earned recognition for its effective and dedicated efforts to continue the advancement of green biologics solutions for a he

PR Newswire 4 months ago

WXIBF

WXXWY
WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced major accomplishments at its cutting-edge greenfield site in Dundalk, Ireland. The site has successfully completed multiple 16,000-liter Process Performance Qualification (PPQ) runs at its MFG7 drug substance suite. So far, the site has completed two PPQ runs with 100% success rate. In addition, all three manufacturing facilities received GMP approval fro

PR Newswire 4 months ago

WXIBF

WXXWY
WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it will enhance its drug product (DP) capabilities at the company's facility in Leverkusen, Germany, with a new sterile filling line for prefilled syringes (PFS) using isolator technology.

PR Newswire 5 months ago

WXIBF

WXXWY
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. The platform, specialized in non-antibiotic cell line development, employs zinc finger nucleases (ZFN) technology for targeted knockout of the endogenous GS gene in CHO cells.

PR Newswire 5 months ago

WXIBF

WXXWY

Performance Overview

Return	1FW2.F	HANG SENG INDEX (^HSI)
YTD	+17.43%	+9.85%
1-Year	+55.50%	+24.17%
3-Year	-60.90%	+4.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

WuXi Biologics (Cayman) Inc. (1FW2.F)

WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards

WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year

WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

WuXi Biologics Included in S&P Global Sustainability Yearbook 2025

WuXi Biologics introduces E coli expression system

WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production

WuXi Biologics Again Passed GMP Inspection by Japan PMDA

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

WuXi Biologics to sell Ireland-based vaccine site to MSD for $500m

Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

Performance Overview